These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31327684)

  • 21. Erenumab Side Effects.
    Robbins L
    Headache; 2019 Jul; 59(7):1088-1089. PubMed ID: 31297805
    [No Abstract]   [Full Text] [Related]  

  • 22. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina.
    Depre C; Antalik L; Starling A; Koren M; Eisele O; Lenz RA; Mikol DD
    Headache; 2018 May; 58(5):715-723. PubMed ID: 29878340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack.
    Juhasz G; Zsombok T; Jakab B; Nemeth J; Szolcsanyi J; Bagdy G
    Cephalalgia; 2005 Mar; 25(3):179-83. PubMed ID: 15689192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. De Novo Visual Aura Onset in a Migraineur on Galcanezumab-Gnlm.
    Kearney E; Collins T; Sengupta S
    Headache; 2020 Jul; 60(7):1435-1437. PubMed ID: 32476127
    [No Abstract]   [Full Text] [Related]  

  • 25. CGRP/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization?
    Majima M; Ito Y; Hosono K; Amano H
    Trends Pharmacol Sci; 2019 Jan; 40(1):11-21. PubMed ID: 30502971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardio- and cerebrovascular safety of erenumab, a monoclonal antibody targeting CGRP receptors - important studies on human isolated arteries.
    Messlinger K; MaassenVanDenBrink A
    Cephalalgia; 2019 Dec; 39(14):1731-1734. PubMed ID: 31526030
    [No Abstract]   [Full Text] [Related]  

  • 28. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L; Haanes KA; Warfvinge K; Krause DN
    Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Insights into the Regulation of CGRP-Family Receptors.
    Gingell JJ; Hendrikse ER; Hay DL
    Trends Pharmacol Sci; 2019 Jan; 40(1):71-83. PubMed ID: 30527443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.
    de Hoon J; Van Hecken A; Vandermeulen C; Yan L; Smith B; Chen JS; Bautista E; Hamilton L; Waksman J; Vu T; Vargas G
    Clin Pharmacol Ther; 2018 May; 103(5):815-825. PubMed ID: 28736918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting erenumab adverse events with single-cell genomics.
    Vgontzas A; Renthal W
    Lancet; 2020 Jul; 396(10244):95-96. PubMed ID: 32653068
    [No Abstract]   [Full Text] [Related]  

  • 33. A Controlled Trial of Erenumab for Episodic Migraine.
    Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks].
    Stepień A; Jagustyn P; Trafny EA; Widerkiewicz K
    Neurol Neurochir Pol; 2003; 37(5):1013-23. PubMed ID: 15174248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paralytic ileus after planned abdominal surgery in a patient on treatment with erenumab.
    Frattale I; Ornello R; Pistoia F; Caponnetto V; Colangeli E; Sacco S
    Intern Emerg Med; 2021 Jan; 16(1):227-228. PubMed ID: 32557089
    [No Abstract]   [Full Text] [Related]  

  • 36. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K; Michael RL; Rapoport AM
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura.
    Altamura C; Viticchi G; Fallacara A; Costa CM; Brunelli N; Fiori C; Silvestrini M; Vernieri F
    Cephalalgia; 2021 Jan; 41(1):90-98. PubMed ID: 32867533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computed Tomography Perfusion Improves Diagnostic Accuracy in Acute Posterior Circulation Stroke.
    Sporns P; Schmidt R; Minnerup J; Dziewas R; Kemmling A; Dittrich R; Zoubi T; Heermann P; Cnyrim C; Schwindt W; Heindel W; Niederstadt T; Hanning U
    Cerebrovasc Dis; 2016; 41(5-6):242-7. PubMed ID: 26820989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
    Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
    J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CGRP antagonists and antibodies for the treatment of migraine.
    Vécsei L; Szok D; Csáti A; Tajti J
    Expert Opin Investig Drugs; 2015 Jan; 24(1):31-41. PubMed ID: 25219387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.